

Nexstim

Nexstim Plc: Invitation to the Annual General Meeting

Company announcement, Helsinki, 15 April 2021 at 12:00 pm (EEST)

The Annual General Meeting of Nexstim Corporation (NXTMH: HEX, NXTMS: STO) (“Nexstim” or the “Company”) will be held on 11 May 2021 at 12:00 PM (EEST). The meeting will be held exceptionally without the presence of shareholders or their representatives at Nexstim’s head office, Elimäenkatu 9 B (courtyard), 4th floor, 00510 Helsinki.

The Board of Directors of the Company has decided on an exceptional general meeting procedure pursuant to the provisional act approved by the parliament on 15 September 2020 (the “Provisional Act”). In order to limit the spread of the COVID-19 pandemic, the Annual General Meeting will be held without the presence of shareholders or their representatives at the venue. This is necessary so that the Annual General Meeting can be held in a predictable manner, taking into account the health and safety of shareholders, company personnel and other stakeholders.

Shareholders and their representatives may attend the meeting and exercise their rights only by voting in advance and by submitting counter-proposals and questions in advance in accordance with this invitation and other instructions of the company.

It is not possible to attend the meeting on the premises. Instructions for shareholders can be found in Part C “Instructions for Meeting Participants” of this invitation.

A. Matters on the agenda of the Annual General Meeting of Shareholders

At the Annual General Meeting of Shareholders, the following matters will be considered:

1 OPENING THE MEETING

2 CALLING THE MEETING TO ORDER

Attorney-at-law Jan Lindberg will act as the chairman. If Jan Lindberg is prevented from acting as chairman for a weighty reason, the Board of Directors will appoint as the chair the person it deems most suitable. The chairman may appoint a secretary for the meeting.

3 ELECTION OF PERSONS TO SCRUTINISE THE MINUTES AND TO SUPERVISE THE COUNTING OF VOTES

Hanna Kotola, the General Counsel of the Company, acts as the scrutiniser of minutes and as the supervisor of counting of votes. If Hanna Kotola is prevented from acting as scrutiniser of minutes and as supervisor of counting of votes, the Board of Directors will appoint the person it deems most suitable to scrutinise the minutes and to supervise the counting of votes.

4 ESTABLISHING THE LEGALITY OF THE MEETING

5 RECORDING THE ATTENDANCE AT THE MEETING AND THE VOTING LIST

Shareholders who have voted in advance during the advance voting period and who have the right to participate in the Annual General Meeting pursuant to Chapter 5, Sections 6 and 6a of the Finnish Companies Act are considered to be shareholders participating in the meeting.

The voting list will be confirmed on the basis of information provided by Euroclear Finland Oy and Euroclear Sweden Ab.

6 PRESENTATION OF THE ANNUAL ACCOUNTS INCLUDING CONSOLIDATED ACCOUNTS, THE REPORT OF THE BOARD OF DIRECTORS AND THE AUDITOR'S REPORT FOR THE YEAR 2020

The company's annual report, which includes the company's financial statements and the report of the Board of Directors and the auditor's report and which is available on the company's website no later than three weeks before the Annual General Meeting, will be deemed to be presented to the Annual General Meeting here.

7 ADOPTION OF THE ANNUAL ACCOUNTS

8 LOSS OF THE FINANCIAL YEAR

The Board of Directors proposes to the Annual General Meeting that no dividend be paid for the financial period 1 Jan – 31 Dec 2020 and that the loss for the financial year be recorded in the loss account.

9 DISCHARGING THE MEMBERS OF THE BOARD OF DIRECTORS AND THE CEO FROM LIABILITY

10 RESOLUTION ON THE NUMBER OF MEMBERS OF THE BOARD OF DIRECTORS

The Nomination Board of Shareholders representing the largest shareholders proposes to the Annual General Meeting that the Board shall have four members.

11 ELECTION OF THE CHAIR AND THE MEMBERS OF THE BOARD OF DIRECTORS

The Nomination Board proposes to the Annual General Meeting that:

- in accordance with their consents to serving on the Board, Mr. Martin Forss and Ms. Leena Niemistö shall be re-elected as members of the Board and Mr. Tero Weckroth and Mr. Timo Hildén shall be elected as new members of the Board.
- Leena Niemistö is elected as Chairman of the Board.

Leena Niemistö is independent of the Company but not independent of Company's major shareholders due to the fact that she together with Kaikarhenni Oy, a company

controlled by Ms. Niemistö, together hold approximately 15,3% (on 8th of April, 2021) of all registered shares and voting rights of the Company. Other proposed members of the Board are independent of the Company and its major shareholders.

The biographies of proposed new Board members are visible in the Company's website at <https://nexstim.com/investors/shareholder-meetings>.

The Nomination Board agrees that proposed new Board members and the entire Board are suitable for the proposed roles individually and collectively, and Leena Niemistö is suitable to act as the Chairman of the Board.

12

RESOLUTION ON THE REMUNERATION OF THE MEMBERS OF THE BOARD OF DIRECTORS AND REIMBURSEMENT OF TRAVEL EXPENSES

The Nomination Board of Shareholders proposes to the Annual General Meeting that the members of the Board of Directors chosen in the Annual General Meeting be remunerated for the period ending at the end of the 2022 Annual General Meeting as follows:

- €36,000 for the Chairman of the Board;
- €25,200 for other members of the Board; and
- No member of the Board of Directors serving in the Nomination Board of Shareholders will be remunerated for their duties on the Nomination Board of Shareholders. a member of the Board of Directors be entitled to remuneration only for the period during which they are a member of the Board of Directors.

According to the company's policy, the cash remuneration is paid in four instalments.

Restricted Share Unit Plan and Allocation for Board Members

The Nomination proposes to the Annual General Meeting that

- the restricted share unit plan implemented first in 2016 be continued for one year for the sixth vesting period (2021–2022) with respect to the elected members of the Board of Directors of Nexstim Plc on the terms and conditions, which can be found at www.nexstim.com
- the target group of the plan be those members of the Board of Directors who are independent of the company. Such a member is, however, not required to be independent of the shareholders of the company
- the rewards allocations in 2021 will be determined as a Euro value

The aim of the plan is to commit the participants to the company, align the objectives of shareholders and participants and thereby increase the value of the company and

Nexstim

to offer the participants a reward plan based on receiving and accumulating the company's shares.

Allocation for Board Members for the Vesting Period 2021–2022

The Nomination Board proposes to the Annual General Meeting that:

- for a Board member, the gross value of the compensation for the vesting period 2021–2022 will be as follows:
 - for the chairman of the Board of Directors: €24,000
 - for a member: €16,800

The granted compensation will be converted into restricted share units at the beginning of the vesting period in 2021. The conversion of the granted reward into restricted share units will be based on the trade-volume-weighted average quotation of the company's share on Nasdaq Helsinki Ltd during twenty (20) trading days following the release date of the company's Annual Accounts of the year 2020. In the plan, one restricted share unit corresponds to one company share. The value of the payable compensation will be determined on the basis of the share price on the book-entry registration date of the paid shares.

- The Nomination Board proposes that the compensations pursuant to the plan be paid to the Board Members in the company's shares within one month of the Annual General Meeting of Shareholders in 2022. Should a Board Member cease to be a member of the Board before the end of a vesting period, no compensation will be paid on that basis.

The company will withhold taxes and employment-related expenses from the cash proportion of the compensation as per applicable law.

Ownership recommendation

The Nomination Board of Shareholders proposes that the Annual General Meeting advise the members of the Board to hold the shares paid as compensation as long as their mandate as a member of the Board continues.

Travel expenses

In addition, the Nomination Board proposes that reasonable travel expenses be reimbursed against receipts to the members of the Board, following the principles of the company's Travel Policy. This applies both to members of the Board of Directors and, to the extent applicable, Board members acting as members of the Nomination Board of Shareholders.

Nexstim

The Board of Directors proposes that PricewaterhouseCoopers Oy, Authorised Public Accountants, which has appointed Authorised Public Accountant Enel Sintonen as the principal auditor, be elected as the Company's auditor for the period ending at the end of the next Annual General Meeting. The proposed auditor has given their consent to the election.

14 RESOLUTION ON THE REMUNERATION OF THE AUDITOR

The Board of Directors proposes that the auditor be paid reasonable remuneration in accordance with the invoice approved by the Company.

15 REDUCING THE QUANTITY OF COMPANY'S SHARES BY WAY OF ISSUING NEW COMPANY SHARES AND BY REDEMPTION OF COMPANY'S OWN SHARES

The Board of Directors of Company proposes to the Annual General Meeting that the Annual General Meeting resolve on the reduction of the quantity of Company's shares without reducing share capital by way of issuing new shares and by redemption of Company's own shares, in such way that each current one hundred shares of the Company correspond to one share of the Company after the completion of the arrangements related to the reduction of the quantity of Company's shares. Prior to the reduction of the quantity of Company's shares, the total number of shares in the company is 663 639 370.

The purpose of the reduction of the quantity of Company's shares is to increase the value of a single share and thus to improve the trade conditions of the shares and the reliability of the price formation of the shares. Thus, the Board of Directors considers that there is a particularly weighty financial reason for the Company to reduce the quantity of Company's shares. This arrangement shall not affect the equity of the Company.

With respect to shareholders registered on the Transaction Day (as defined below) in the shareholders' register of Nexstim maintained by Euroclear Finland Ltd, the reduction of the quantity of shares shall be carried out as follows:

It is proposed that the reduction of the quantity of Company's shares be carried out so that the Company on 14 May 2021 (the "**Transaction Day**") issue new Company shares to each such shareholder of the Company without consideration so that the number of all shares per book-entry accounts owned by the shareholders of the Company are divisible by the number 100. The maximum quantity of the Company's own shares transferred by the Company shall be 100-1 shares multiplied by the number of such book-entry accounts on the Transaction Day, on which the Company's shares are held, and which are owned by the shareholders of the Company. Based on the Board of Director's estimate on the number of Company's shareholders of Nexstim on the date of this proposal, it is proposed that the maximum amount of new shares issued by the Company in the share issue to such shareholders be 1,000,000 () new shares of the Company (calculated maximum number of shares in case each of the

Nexstim

10 000 shareholders will require full increase). The Board of Directors of the Company is entitled to resolve on all other matters related to the issuance of shares without consideration

On the Transaction Day, at the same time with the aforementioned issue of the Company's new shares, the Company shall redeem without consideration a number of shares from each such shareholder of the Company. The number of shares to be redeemed by the Company will be determined according to the redemption ratio of 100/1 based on the ownership of such shareholders on the Transaction Day. In other words, for every 100 shares of the Company, 100-1 Company shares shall be redeemed. The Board of Directors of the Company shall be entitled to resolve on all other matters related to the redemption of shares.

The Company's shares, which are redeemed in connection with the reduction of the quantity of Company's shares, shall be annulled immediately following the redemption by a resolution of the Board of Directors of the Company. The reduction of the quantity of the Company's shares shall be carried out in the book-entry system at the end of trading day on Nasdaq Helsinki on 14 May 2021, i.e., on the Transaction Day (i.e., on the record day). The annulment of the shares and the Company's new total number of shares are entered in the trade register by 17 May 2021. Trading with the Company's new total number of shares on Nasdaq Helsinki with new ISIN code will begin approximately on 17 May 2021, on which date the reduced number of shares will also appear on each book entry account of the shareholders registered in the shareholders' register of Nexstim maintained by Euroclear Finland Ltd.

With respect to shareholders with shares registered in a) Euroclear Sweden AB's Securities System (whether registered in the name of or a nominee or directly of the shareholder) and b) holders of nominee registered shares registered in Euroclear Finland Ltd's Book-entry System, the reduction of the quantity of shares shall be carried out as follows:

For the purposes of execution of the reduction of the number of shares, the Board of Directors also proposes that the Annual General Meeting of shareholders pass the resolution on the issuance of a maximum of 350,000 new shares to the Company itself without payment. The directed share issue is connected to the completion of the reduction of the number of shares and justified by the reasons set forth above in this section. For the sake of clarity, the number of shares to be issued to the Company itself is calculated based on the number of shares prior to the reduction in the Company, and not the number of the reduced shares.

The shares issued to the Company itself are to be re-issued, i.e., transferred from the Company without consideration to such shareholders (the "Receiving Shareholders") holding on the Record Day (as defined below) a) shares registered in Euroclear Sweden AB's Securities System, whether registered in the name of or a nominee or directly of the Shareholder, or b) nominee-registered shares registered in Euroclear Finland Ltd's

Nexstim

Book-entry System, the amount of which (a or b) is not divisible by 100, to the extent required by their shareholding in the Company being divisible by the number 100. The Board of Directors is hereby authorised to pass a resolution on transfer of such shares from the Company to the Receiving Shareholders as well as to decide on the terms related to such share issue(s)/transfers.

In connection with the redemption of the Company's shares held by shareholders registered in the shareholders' register of Nexstim maintained by Euroclear Finland Ltd, the Company will also redeem without consideration a number of shares from each Receiving Shareholder. The number of shares to be redeemed by the Company will be determined according to the redemption ratio of 100/1 based on ownership of the Company's shares by the Receiving Shareholders on the Transaction Day (according to share and shareholder information available with Euroclear Finland Oy) to execute the reduction of the number of shares, and such number(s) of reduced shares (per each Receiving Shareholder) are then adjusted, if needed, by the abovementioned transfer of shares to the Receiving Shareholders based on their actual ownership of the Company's shares on the Record Day (as defined below). The Board of Directors of the Company shall be entitled to resolve on all other matters related to the redemptions of shares.

The Company's shares, which are redeemed in connection with the reduction of the quantity of the Company's shares, shall be annulled immediately following the redemption by a resolution of the Board of Directors of the Company.

The shares issued to the Company itself will be registered in the trade register by 17th of May 2021. Trading with the Company's new total number of shares on Nasdaq Stockholm (and Nasdaq Helsinki) with new ISIN code will begin approximately on 17th of May 2021 ("**Trading Day**"). The record day (the "**Record Day**") for the reduction of the quantity of Company's shares shall be a) with respect to shares registered in Euroclear Sweden AB's Securities System (whether registered in the name of or a nominee or directly of the shareholder) 18th of May 2021 and b) with respect to nominee-registered shares registered in Euroclear Finland Ltd's Book-entry System 14th of May 2021. The transfers of shares from the Company to the Receiving Shareholders required for the final adjustments of their number of shares (after reduction) are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Sweden and 19th May 2021 in Finland.

Any own shares in the possession of the Company after transactions with the Receiving Shareholders will be annulled. The arrangement, if it is realised, will not require the shareholders to take any action. No part of the arrangement shall be carried out unless all the other parts of the arrangement are carried out as well.

If necessary, the trading with the Company's share on Nasdaq Helsinki or Nasdaq Stockholm shall be temporarily interrupted in order to perform the necessary technical measures in the trading facility after the Transaction Day.

If the proposal of the Board of Directors is accepted as set forth above, it was noted that the authorised maximum amount of shares that may be issued under all outstanding authorisations (whether as new or existing shares or option rights or other rights to shares) shall also be divisible in accordance with the above-mentioned principle.

16

AUTHORISING THE BOARD OF DIRECTORS TO DECIDE ON ISSUANCE OF SHARES AS WELL AS ISSUANCE OF OPTION RIGHTS AND OTHER SPECIAL RIGHTS ENTITLING TO SHARES

The Board of Directors proposes to the Annual General Meeting that the Board of Directors be authorised to decide on (i) the issuance of new shares and/or (ii) the transfer of the Company's own shares and/or (iii) the issuance of special rights referred to in Chapter 10, Section 1 of the Companies Act with the following terms:

Right to shares:

New shares may be issued and the Company's own shares transferred

- to the Company's shareholders in proportion to their current shareholdings in the Company; or
- deviating from the shareholders' pre-emptive right through one or more directed share issue, if the Company has a weighty financial reason to do so, such as the use of shares as consideration for possible acquisitions or other arrangements related to the company's business (including the arrangement described in section 15 above regarding the reducing of the quantity of the Company's shares), financing of investments.

The new shares can also be issued to the Company itself free of charge. Share issue against payment and without payment: New shares may be issued and treasury shares held by the Company may be transferred either against payment (Share issue against payment) or free of charge (Share issue without payment). A directed share issue can only be without payment if there is a particularly weighty financial reason for it from the Company's point of view and taking into account the interests of all its shareholders.

The maximum number of shares:

Pursuant to the authorisation, the Board of Directors is entitled to decide on the issuance of new shares and/or the transfer of the Company's own shares so that the total number of issued and/or transferred shares does not exceed 130,000,000, when the current number of the Company's registered shares is 663 639 370, if the proposals set forth in section 15 are not approved. If the proposals set forth in section 15 are approved, the authorization will be adjusted correspondingly.

Issuance of special rights:

The Board of Directors may issue special rights referred to in Chapter 10, Section 1 of the Companies Act, which entitle the holder to receive new shares or the Company's own shares in against payment. The right may also be granted to the Company's creditor in such a way that the right is subject to the condition that the creditor's claim be used to set off the share subscription price (convertible bond).

The number of new shares to be subscribed to under the special rights granted by the Company and the number of treasury shares to be transferred held by the Company may not exceed a total of 130,000,000, which is included in the maximum number mentioned in the "Maximum number of shares" -section above. Subject to approval of proposals in this section 15 the authorization shall be changed correspondingly.

Recording of the subscription price in the balance sheet:

The subscription price of the new shares and the amount to be paid for the Company's own shares must be entered in the invested unrestricted equity fund.

Other terms and validity:

The Board of Directors decides on all other matters related to the authorisations.

The authorisations are valid for eighteen (18) months from the decision of the Annual General Meeting. The proposed authorisation does not invalidate prior resolved and registered authorisations made by the General Meeting of Shareholders regarding share issue, issuing of option rights and other special rights entitling to shares.

17

AUTHORISATION INTENDED TO BE USED FOR THE BOARD'S RSU PLAN AND FOR THE LONG-TERM INCENTIVE PLANS FOR THE MANAGEMENT AND THE PERSONNEL OF THE COMPANY

The Board of Directors proposes to the Annual General Meeting that the Board of Directors be authorised to decide on (i) the issuance of new shares and/or (ii) the transfer of the Company's own shares and/or (iii) the issuance of special rights referred to in Chapter 10, Section 1 of the Companies Act with the following terms:

The shares issued under the authorisation are new or those in the Company's possession. Based on and within the limits of this authorisation, the Board of Directors can also decide on issuance(s) of option rights or other special rights set forth in Chapter 10 the Companies Act complementing or replacing issuance(s) of shares.

Nexstim

The new shares can also be issued to the Company itself free of charge. Share issue against payment and without payment: New shares may be issued, and treasury shares held by the Company may be transferred either against payment (Share issue against payment) or free of charge (Share issue without payment). A directed share issue can only be without payment if there is a particularly weighty financial reason for it from the Company's point of view and taking into account the interests of all its shareholders.

Under the authorisation, a maximum of 5 500 000 shares may be issued, which corresponds to approximately 0,82% percent of all the shares in the Company after the share issue, provided that new shares are issued, considering all registered shares of the Company. Subject to approval of proposals in this section 15 the authorization shall be changed correspondingly

The shares, option rights and/or other special rights entitling to shares can be issued in one or more tranches.

The Board of Directors is authorised to resolve on all terms for the share issues and the terms for the granting of the option rights and other special rights entitling to shares. The Board of Directors is authorised to resolve on a directed share issue and issue of the special rights entitling to shares in deviation from the shareholders' pre-emptive right, provided that there is a weighty financial reason for the Company to do so.

The authorisation is valid for five (5) years from the decision of the Annual General Meeting of Shareholders. The authorisation may be used for the implementation of the RSU plan for the members of the Board of Director's and for the long-term incentive plans for the management and the personnel of the Company. The authorisation can also be used for incentive arrangements and payment of the Board fees.

The proposed authorisation does not invalidate prior resolved and registered authorisations made by the General Meeting of Shareholders regarding share issue, issuing of option rights and other special rights entitling to shares.

18 CLOSING OF THE MEETING

B. Documents of the Annual General Meeting of Shareholders

This invitation to the Annual General Meeting, which includes the proposals made to the Annual General Meeting and the Remuneration Report, is available on Nexstim Plc's website at <https://nexstim.com/investors/shareholder-meetings/> as well as at the Company's head office. The Remuneration Report of the Company is attached to this invitation to the Annual General Meeting. The Annual accounts, Consolidated accounts, report of the Board of Directors and Auditor's report are available on the

Nexstim

abovementioned website no later than 20 April 2021. The minutes of the Annual General Meeting are available in the abovementioned website no later than 25 May 2021.

C. Instructions for the participants of the Annual General Meeting of Shareholders

In order to limit the spread of the COVID-19 pandemic, the Annual General Meeting will be held in such a way that shareholders or their representatives will not be able to attend the meeting physically. The Company's shareholders and their representatives may attend the meeting and exercise their rights only by voting in advance and by submitting counter-proposals and questions in advance, taking into account the limitations of the Provisional Act.

A shareholder or proxy cannot participate in the meeting via a real-time data connection either.

1. Shareholders registered in the shareholders' register

Each shareholder registered on 29 April 2021 in the shareholders' register of Nexstim maintained by Euroclear Finland Ltd has the right to participate in the Annual General Meeting of Shareholders. A shareholder whose shares are registered on their personal book-entry account is registered in the shareholders' register of Nexstim.

2. Registration and voting in advance of a shareholder entered in the shareholder register

Registration and advance voting will begin on 20 April 2021, when the deadline for submitting counter-proposals for voting has expired and the Company has published any counter-proposals for voting on the Company's website. A shareholder entered in the Company's shareholder register who wishes to participate in the Annual General Meeting must register for the Annual General Meeting and vote in advance no later than 6 May 2021 at 10:00 am (EEST), by which time the registration and votes must be received.

Shareholders may register and vote in advance between 20 April 2021 and 6 May 2021 at 10:00 am (EEST) in the following ways:

a) Via the Company's website <https://nexstim.com/investors/shareholder-meetings/>; For registration and advance voting, strong electronic authentication (online banking ID or Mobile Certificate) is required for natural persons, as well as a business ID and book-entry account number for legal entities.

b) By mail or e-mail: a shareholder voting in advance by mail or e-mail must mail the advance voting form available on the Company's website to Euroclear Finland Oy following address, Euroclear Finland Oy, Annual General Meeting/Nexstim Oyj, P.O. Box 1110, 00101 Helsinki, or by e-mail to yhtiokokous@euroclear.eu.

Nexstim

If a shareholder participates in the Annual General Meeting by mailing advance votes to Euroclear Finland Oy, submitting votes before the deadline for registration and advance voting is considered registration to the Annual General Meeting, provided that the shareholder's message contains the information required for registration, the requested information, such as the shareholder's identification and contact information, must be provided. Personal data provided by shareholders in connection with the registration will only be used in connection with the Annual General Meeting and the processing of the necessary registrations related thereto. Voting instructions for all shareholders are available on the Company's website at <https://nexstim.com/investors/shareholder-meetings/>.

Further information is also available during registration time by telephone at +35892727170 from Monday to Friday from 9:00 a.m. to 4:00 p.m. (EEST)

3. Proxy representative and powers of attorney

A shareholder may participate in the Annual General Meeting of Shareholders and exercise their rights at the Meeting by way of proxy representation.

A proxy representative shall produce a proxy document with a date or otherwise in a reliable manner demonstrate their right to represent the shareholder at the Annual General Meeting of Shareholders.

When a shareholder participates in the Annual General Meeting of Shareholders by means of several proxy representatives representing the shareholder with shares at different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the Annual General Meeting of Shareholders.

The template for the power of attorney and voting instructions will be available on the Company's website <https://nexstim.com/investors/shareholder-meetings/> no later than 20 April 2021, when the deadline for submitting counter-proposals for voting has expired and the Company has published any counter-proposals for voting on the Company's website.

A shareholder who does not vote in advance may use the power of attorney service provided by the Company free of charge and authorises Leena-Maija Marsio from Attorneys at Law Trust Ltd or another lawyer independent of the Company appointed by them to represent the shareholder and to exercise their voting right at the meeting in accordance with the voting instructions given by the shareholder.

A signed power of attorney including the advance voting form must be submitted to counsel Leena-Maija Marsio by mail or e-mail (contact information below) before the end of registration period and voting time, by which time the said documents must be received. A presentation of the agent appointed by the Company, Leena-Maija

Nexstim

Marsio, can be found on the website <https://www.thetrust.fi/staff/leena-maija-marsio/>

and their contact details are: mailing address: Asianajotoimisto Trust Oy, Fredrikinkatu 39 B 15, 00120 Helsinki e-mail: leenamaija.marsio@thetrust.fi.

A shareholder may also participate in the Annual General Meeting and exercise their rights there through another proxy of their choice. The proxy chosen by the shareholder must also vote in advance by mail or e-mail as described in this invitation (the proxy cannot vote through the electronic advance voting system).

The proxy must mail the received power of attorney including the advance voting form or similar information to Euroclear Finland Oy, Annual General Meeting/Nexstim Oyj, P.O. Box 1110, 00101 Helsinki or by e-mail to yhtiokokous@euroclear.eu, to be received before the end of the registration period and voting time.

Receipt of a power of attorney by Euroclear Finland Oy before the end of the registration period is considered registration for the Annual General Meeting.

Holders of nominee-registered shares

A holder of nominee-registered shares has the right to participate in the Annual General Meeting by virtue of such shares, based on which they, on the record date of the Annual General Meeting, i.e., on 29 April 2021, would be entitled to be registered in the shareholders' register of Nexstim held by Euroclear Finland Ltd. The right to participate in the Annual General Meeting also requires that the shareholder, on the basis of such shares, has been registered into the temporary shareholders' register maintained by Euroclear Finland Ltd at the latest by 6 May 2021 at 10:00 a.m. (EEST). As regards nominee registered shares this constitutes due registration for the Annual General Meeting.

A holder of nominee-registered shares is advised to request without delay, from their custodian bank, the necessary instructions regarding the registration in the shareholders' register of Nexstim, the issuing of proxy documents and registration for the Annual General Meeting of Shareholders. The account management organisation of the custodian bank has to register a holder of nominee-registered shares who wants to participate in the Annual General Meeting into the temporary shareholders' register of Nexstim at the latest by the time stated above.

3. Shares registered with Euroclear Sweden AB

A shareholder with shares registered with Euroclear Sweden AB's Securities System who wishes to attend and vote at the Annual General Meeting must:

- be registered in the shareholders' register maintained by Euroclear Sweden AB no later than on 29 April 2021.

Nexstim

- Shareholders, whose shares are registered in the name of a nominee must, in order to be eligible to request a temporary registration in the shareholders' register of Nexstim Plc maintained by Euroclear Finland, request that their shares are re-registered in their own names in the register of shareholders maintained by Euroclear Sweden AB, and procure that the nominee sends the above request for temporary registration to Euroclear Sweden AB on their behalf. Such registration must be made at the latest by 3 May 2021 and the nominee should therefore be notified well in advance before said date.
- request temporary registration in the shareholders' register of Nexstim Plc maintained by Euroclear Finland Oy. Such request shall be submitted in writing to Euroclear Sweden AB no later than on 3 May 2021 at 5:00 p.m. Swedish time.

4. Making counter-proposals to resolution proposals

Shareholders holding at least one hundredth of all the Company's shares within the meaning of the Provisional Act have the right to make a counter-proposal to the resolution proposals on the agenda of the Annual General Meeting.

Such counter-proposals must be submitted to the Company by e-mail to agm@nexstim.com no later than 10:00 a.m. (EEST) on 19 April 2021.

Shareholders who make a counter-proposal must submit a statement of their shareholding in connection with the submission of the counter-proposal.

The counter-proposal will be considered by the Annual General Meeting on the condition that the shareholder has the right to participate in the Annual General Meeting, the shareholder has registered for the Annual General Meeting and the shareholder still owns at least one hundredth of all shares on the record date.

If the counter-proposal is not considered by the General Meeting, the votes cast in favour of the counter-proposal shall be disregarded. The Company will publish any counter-proposals to be put to the vote on the Company's website <https://nexstim.com/investors/shareholder-meetings/> no later than 20 April 2021.

5. Other instructions/information and advance questions

Until 28 April 2021, a shareholder may ask questions referred to in Chapter 5, Section 25 of the Companies Act by e-mail addressed to agm@nexstim.com.

Such shareholder questions, the Company's answers to them and any non-voted counter-proposals will be available on the Company's website <https://nexstim.com/investors/shareholder-meetings/> no later than 4 May 2021. A prerequisite for asking questions is that the shareholder submits a statement of their shareholding upon request.

Nexstim

On the date of this invitation to the meeting, 15 April 2021, Nexstim Plc has a total of 663 639 370 shares and votes.

Helsinki 15 April 2021

NEXSTIM PLC

Board of Directors

Further information is available on the website www.nexstim.com or by contacting:

Leena Niemistö, Chairman of the Board

+358 9 2727 170

leena.niemisto@nexstim.com

Erik Penser Bank AB (Certified Adviser)

+46 8 463 83 00

certifiedadviser@penser.se

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim's proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Nexstim